(141 days)
Not Found
No
The document does not mention AI, ML, or related terms, and the description focuses on standard vital signs monitoring and data transmission.
No.
The device is a vital signs monitor and telemedicine system used for monitoring and recording physiological parameters, not for treating or preventing disease.
Yes
The Tempus Pro is described as a "portable vital signs monitor" that performs various measurements such as ECG, NIBP, SpO2, and ETCO2. These measurements are used by clinicians to assess a patient's physiological state, which is a key function of a diagnostic device. While it doesn't state it provides a definitive diagnosis, the data it collects is integral to the diagnostic process.
No
The device description clearly states it is a "multi-parameter vital signs monitor" and details various hardware components and sensors (ECG, pulse oximetry, NIBP, capnometry, temperature, etc.). The testing summary also includes hardware-specific tests (environmental, ingress protection, EMC, invasive pressure, pulse oximeter). While it includes software for data transmission and potentially interpretation (12 Lead ECG), it is fundamentally a hardware device with integrated software.
Based on the provided information, the Tempus Pro is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Definition of IVD: IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- Tempus Pro's Function: The Tempus Pro is a vital signs monitor that measures physiological parameters directly from the patient's body (ECG, NIBP, SpO2, temperature, etc.). It does not analyze samples taken from the body.
- Intended Use: The intended use clearly states it's for "attended or unattended monitoring of single or multiple vital signs." This is in-vivo monitoring, not in-vitro analysis.
Therefore, the Tempus Pro falls under the category of a vital signs monitor, which is a different type of medical device than an IVD.
N/A
Intended Use / Indications for Use
"The Tempus Pro is a portable vital signs monitor intended to be used by clinicians and medically qualified personnel for the attended or unattended monitoring of single or multiple vital signs in clinical and pre-hospital care applications. The device is indicated for 3 & 5 Lead ECG monitoring and 12 Lead ECG recording with interpretation, impedance pneumography, non-invasive blood pressure (NIBP), end-tidal CO2 (ETCO2), respiration rate, pulse oximetry (SpO2), contact temperature, invasive pressure and extended pulse oximetry capability including; carboxy haemoglobin (SpCO), metheglobin (SpMet), total haemoglobin (SpHb) and total oxygen content (SpOC) measurements.
The monitor is intended to be used as a stand-alone monitor or as a telemedicine system (transmitting patient data to other medical professionals located elsewhere)."
The device is indicated for adults, pediatrics and neonates.
Product codes (comma separated list FDA assigned to the subject device)
MWI, DRT, DPS, DSB, DXN, CCK, MNR, DQA, FLL, DSK, DRG
Device Description
The Tempus Pro is a multi-parameter vital signs monitor designed for use in pre-hospital care and remote clinical locations by trained healthcare professionals. It provides 3&5 lead ECG monitoring, 12 lead ECG recording, pulse oximetry, non-invasive blood pressure, sidestream capnometry, contact temperature, impedance respiration, invasive pressure and user configurable alarms.
In addition, it provides the ability to transmit all vital signs data via wired or wireless connections to a software system (called i2i) expected to be based in a facility far from the user e.g. a response centre facility. In addition to sending all vital signs, the system can also send pictures or video via an integrated camera, geographic position by an integrated GPS receiver and voice via a wired or wireless headset.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
adults, pediatrics and neonates.
Intended User / Care Setting
clinicians and medically qualified personnel / clinical and pre-hospital care applications.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-Clinical Testing:
Safety: The device has been tested to IEC60601-1.
Defibrillation and electrosurgical protection: The device has been tested for operation with a defibrillator and operation with an electro-surgical unit according to IEC60601-1 (and relevant particular standards).
Environmental: The device has been tested to a range of environmental (temperature, altitude, humidity, vibration, shock) tests according to RTCA DO-160, MIL810, EN1789, EN13718-1, EN60068.
Ingress Protection: The device has been tested to IEC 60529 for solid and water ingress.
EMC: The device has been tested to IEC 60601-1-2 for emissions and immunity and RTCA DO-160 for radiated emissions. (including immunity at 20 V/m)
Invasive pressure: The device has been tested to IEC 60601-2-34.
Pulse oximeter: The device has been tested to IEC 9919.
Comparative testing to predicates: Comparative testing has been performed to demonstrate that the performance of the device is equivalent to the predicates.
Software: The requirements of the FDA document Guidance for the Content of Premarket Submissions for Software in Pre-Market Submissions has been applied. In addition, the requirements of IEC 62304 have been addressed.
Bench testing: All parameters of the device have been tested to confirm they operate to specification across their stated performance range and across their stated temperature range.
Bench testing: The product has been bench tested to confirm that all data is transmitted reliably and accurately.
Wireless co-existence testing: The thermometer has been tested to confirm it operates reliably in the presence of other wireless fields as per the FDA Guidance for Radio-Frequency Wireless Technology in Medical Devices.
Key results: In each case the results of this testing confirmed that acceptance criteria defined by the relevant standard, or other appropriate reference document had been met.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).
0
K133988 Page 1 of 4
RDT Abbreviated 510(k) Submission - Tempus Pro (EF)
5. 510(k) Summary of Safety and Effectiveness
MAY 1 6 2014
5.1 Submitter's Information
i
The submitter of this abbreviated pre-market notification is:
| Name: | Remote Diagnostic Technologies Limited |
|---|---|
| Address: | The Old Coach House, Farleigh Wallop, Basingstoke, RG25 |
| 2HT, United Kingdom | |
| Company Phone No: | +44 (0) 1256 362 400 |
| Company Fax No: | +44 (0) 1256 362 415 |
| Contact Person: | Dr Leigh Cornock (Director of Systems Eng. & Test) |
| Date summary prepared: | 10th April, 2014 |
5.2 Device Identification
| Device Trade Name: | Tempus Pro |
|---|---|
| Common Name: | Patient Monitor (without arrhythmia detection or alarms) |
| Class: | II |
| Classification Panel: | 74 |
| Primary Product Code: | MWI |
| Primary Regulation Number: | 870.2300 |
| Secondary FDA product code | Regulation Number |
|---|---|
| Cardiac Monitor (DRT) | 870.2300 |
| Electrocardiograph (DPS) | 870.2340 |
| Impedance Plethysmograph (DSB) | 870.2770 |
| Non Invasive Blood Pressure Measurement System (DXN) | 870.2770 |
| Carbon Dioxide Gas Analyzer (CCK) | 868.1400 |
| Breathing frequency monitor (MNR) | 868.2375 |
| Oximeter (DQA) | 870.2700 |
| Clinical electronic thermometer (FLL) | 880.2910 |
| Computer, Blood-pressure (DSK) | 870.1110 |
| Transmitters and Receivers, Physiological Signal, Radiofrequency (DRG) | 870.2910 |
5.3 Device Description
The Tempus Pro is a multi-parameter vital signs monitor designed for use in pre-hospital care and remote clinical locations by trained healthcare professionals. It provides 3&5 lead ECG monitoring, 12 lead ECG recording, pulse oximetry, non-invasive blood pressure, sidestream capnometry, contact temperature, impedance respiration, invasive pressure and user configurable alarms.
In addition, it provides the ability to transmit all vital signs data via wired or wireless connections to a software system (called i2i) expected to be based in a facility far from the user e.g. a response centre facility. In addition to sending all vital signs, the system can also send pictures or video via an integrated camera, geographic position by an integrated GP$ receiver and voice via a wired or wireless headset.
1
RDT Abbreviated 510(k) Submission - Tempus Pro (EF)
5.4 Indications for Use
The following indications for the Tempus Pro remain unchanged by addition of the extended features for ECG recording, pulse oximetry and invasive blood pressure monitoring to the Tempus Pro, with the exception of removal of "(SpO2)" as additional pulse oximetry measurements are being added.
"The Tempus Pro is a portable vital signs monitor intended to be used by clinicians and medically qualified personnel for the attended or unattended monitoring of single or multiple vital signs in clinical and pre-hospital care applications. The device is indicated for 3 & 5 Lead ECG monitoring and 12 Lead ECG recording with interpretation, impedance pneumography, non-invasive blood pressure (NIBP), end-tidal CO2 (ETCO2), respiration rate, pulse oximetry (SpO2), contact temperature, invasive pressure and extended pulse oximetry capability including; carboxy haemoglobin (SpCO), metheglobin (SpMet), total haemoglobin (SpHb) and total oxygen content (SpOC) measurements.
The monitor is intended to be used as a stand-alone monitor or as a telemedicine system (transmitting patient data to other medical professionals located elsewhere).
The device is indicated for adults, pediatrics and neonates."
5.5 Comparison with Cleared Device
The intended use and indications for use, plus the fundamental technology used in the Tempus Pro device, remain essentially unchanged by the addition of optional extended features to the ECG recording, pulse oximetry, and invasive blood pressure functions, which are specifically:
- I Extended Pulse Oximetry capability to include optional carboxy haemoglobin (SpCO). metheglobin (SpMet) total haemoglobin (SpHb) and total oxygen content (SpOC) measurements
- . Optional 12-Lead ECG Recording Interpretation
- . 2 optional additional Invasive Blood Pressure Channels
5.6 Substantial Equivalence
In adding some of the optional features, it has been necessary to cite other predicates for specific functionality provided:
- . Pulse Oximetry - new Masimo SET Rainbow module and associated sensors/patient cable, incorporating original SET oxygen saturation technology as used in cleared Tempus Pro plus 4 new measurement capabilities, is substantially equivalent to the same module incorporated into the Masimo Radical-7 device (K110028)
- I Invasive Blood Pressure - additional external IBP module which uses same Medlab IBP module as already incorporated internally into the cleared Tempus Pro device (K130773)
- ECG Recording Interpretation enabling the interpretation output of the ■ mymisys32.dll, which is already an integral part of the cleared Tempus Pro, but the interpretation output is not currently displayed to the user. The dll is part of the CardioView software package from QRS Diagnostic (K083749).
2
RDT Abbreviated 510(k) Submission - Tempus Pro (EF)
Hence, the new pulse oximetry module with sensors and cables, the additional invasive blood pressure, and the ECG recording 12 lead interpretation are the same as those used by the original equipment manufacturers in their cleared devices.
The 510(k) numbers for the predicate devices to which we are claiming substantial equivalence are K110028, K130773, and K083749.
5.7 Summary of Non-Clinical Testing
i
ﺮ ﺍ
All of the above modifications have been made under well-established design control procedures, which ensure that appropriate risk management processes have been carried out to determine their impact and ensure that appropriate verification/ validation testing is performed.
The non-clinical testing carried out in relation to addition of the extended features described above is summarized in the following table:
| Area | Testing Performed |
|---|---|
| Safety | The device has been tested to IEC60601-1. |
| Defibrillation and | |
| electrosurgical | |
| protection | The device has been tested for operation with a defibrillator |
| and operation with an electro-surgical unit according to | |
| IEC60601-1 (and relevant particular standards). | |
| Environmental | The device has been tested to a range of environmental |
| (temperature, altitude, humidity, vibration, shock) tests | |
| according to RTCA DO-160, MIL810, EN1789, EN13718-1, | |
| EN60068. | |
| Ingress Protection | The device has been tested to IEC 60529 for solid and water |
| ingress. | |
| EMC | The device has been tested to IEC 60601-1-2 for emissions |
| and immunity and RTCA DO-160 for radiated emissions. | |
| (including immunity at 20 V/m) | |
| Invasive pressure | The device has been tested to IEC 60601-2-34. |
| Pulse oximeter | The device has been tested to IEC 9919. |
| Comparative testing to | |
| predicates | Comparative testing has been performed to demonstrate that |
| the performance of the device is equivalent to the predicates. | |
| Software | The requirements of the FDA document Guidance for the |
| Content of Premarket Submissions for Software in Pre-Market | |
| Submissions has been applied. In addition, the requirements | |
| of IEC 62304 have been addressed. | |
| Bench testing | All parameters of the device have been tested to confirm they |
| operate to specification across their stated performance range | |
| and across their stated temperature range. | |
| Bench testing | The product has been bench tested to confirm that all data is |
| transmitted reliably and accurately. |
3
RDT Abbreviated 510(k) Submission - Tempus Pro (EF)
| Area | Testing Performed |
|---|---|
| Wireless co-existence testing | The thermometer has been tested to confirm it operates reliably in the presence of other wireless fields as per the FDA Guidance for Radio-Frequency Wireless Technology in Medical Devices. |
In each case the results of this testing confirmed that acceptance criteria defined by the relevant standard, or other appropriate reference document had been met.
With respect to usability, no additional user validation was considered necessary, as the Tempus Pro (EF) is almost identical to the predicate Tempus Pro in terms of physical and interface features, including size and weight, user interface data layouts, button styles, menus, and layout of connectors, resulting the physical interaction with the device being unchanged.
5.8 Conclusion
In accordance with the Federal Food, Drug and Cosmetic Act, 21 CFR Part 807 and based on the information provided in this Premarket Notification, Remote Diagnostic Technologies Limited conclude that this extended version of the Tempus Pro Patient Monitor is safe and effective, and substantially equivalent to the unmodified version of this device and other cleared devices used as predicates.
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
Image /page/4/Picture/3 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized symbol to the right and text arranged in a circle to the left. The text reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA". The symbol is a stylized representation of a human figure.
May 16, 2014
Remote Diagnostic Technologies Ltd. · Dr. Leigh Cornock Director of Systems Engineering and Test The Old Coach House, The Avenue Farleigh Wallop, Basingstoke, Hampshire, UK
K133988 Re:
Trade/Device Name: Tempus pro extended features Regulation Number: 21 CFR 870.2300 Regulation Name: Monitor, Physiological, Patient (Without Arrhythmia Detection or Alarms) Regulatory Class: Class II Product Codes: MWI, DRT, DPS, DSB, DXN, CCK, MNR, DQA, FLL, DSK, DRG Dated: April 14, 2014 Received: April 23, 2014
Dear Dr. Leigh Cornock,
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
5
Page 2 - Leigh Cornock
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely vours
forBram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Indications for Use Statement
K133988 Page 1 of 1
510(k) Number (if known):
Device Name: Tempus Pro (EF)
Indications for Use:
The Tempus Pro is a portable vital signs monitor intended to be used by clinicians and medically qualified personnel for the attended or unattended monitoring of single or multiple vital signs in clinical and pre-hospital care applications. The device is indicated for 3 & 5 Lead ECG monitoring and 12 Lead ECG recording with interpretation, impedance pneumography, non-invasive blood pressure (NIBP), endtidal CO2 (ETCO2), respiration rate, pulse oximetry (SpO2), contact temperature, invasive pressure and extended pulse oximetry capability including; carboxy haemoglobin (SpCO), metheglobin (SpMet), total haemoglobin (SpHb) and total oxygen content (SpOC) measurements.
The monitor is intended to be used as a stand-alone monitor or as a telemedicine system (transmitting patient data to other medical professionals located elsewhere).
The device is indicated for adults, pediatrics and neonates.
Prescription Use V_ (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use _ (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Date:
2014.05.16
12:28:44 -04'00'